Can Medroxyprogesterone Acetate Be Used for Contraception?
Yes, medroxyprogesterone acetate (DMPA) is FDA-approved and highly effective for contraception, with a failure rate of 0-0.7% in the first year of use. 1
FDA-Approved Indication
DMPA is specifically indicated for pregnancy prevention and is classified as a long-term injectable contraceptive when administered at 3-month (13-week) intervals 1. The FDA approval establishes this as a primary, evidence-based contraceptive method, not an off-label use.
Available Formulations
Two formulations are available for contraceptive use:
The subcutaneous formulation can be self-administered, which enhances reproductive autonomy and improves access to contraception 2. While FDA labeling states DMPA-SC should be administered by healthcare professionals, self-administration is considered acceptable off-label use when prescribed by a provider 2.
Initiation and Timing
DMPA can be started anytime if the provider is reasonably certain the patient is not pregnant 3. If initiated more than 7 days after menses started, patients should abstain from intercourse or use barrier methods for 7 days 3. No pelvic examination is required before initiation 3, only blood pressure measurement is needed 3.
Efficacy
DMPA demonstrates exceptional contraceptive efficacy with 12-month failure rates of 0-0.7% 1. This effectiveness is dependent on patients returning every 13 weeks for reinjection, though injections can be given up to 2 weeks late (15 weeks from last injection) without requiring additional contraceptive protection 2.
Critical Safety Consideration: Bone Mineral Density
The most significant concern with DMPA is loss of bone mineral density (BMD), which is particularly important in adolescents and young adults during peak bone accretion 1.
Key BMD findings:
- Adult women show spine and hip BMD decreases of 5-6% over 5 years 1
- Most pronounced loss occurs in the first 2 years of use 1
- Partial recovery occurs after discontinuation, but longer treatment duration correlates with less complete recovery 1
- DMPA should be used long-term (>2 years) only if other methods are inadequate 1
For patients with osteoporosis risk factors (metabolic bone disease, chronic alcohol/tobacco use, anorexia nervosa, family history of osteoporosis, chronic corticosteroid use), alternative contraceptive methods should be strongly considered 1.
Advantages in Specific Populations
DMPA is particularly appropriate for:
- Postpartum and lactating women: No interference with lactation 4, can be initiated immediately postpartum 4
- Women with estrogen contraindications: Including those >35 who smoke, history of thromboembolism, cardiovascular disease, liver disease, or complex migraines 1
- Women seeking user-controlled methods: Self-administered DMPA-SC provides autonomy 2
Common Side Effects and Management
Menstrual irregularities are the most common side effect, with initial irregular bleeding and spotting that typically progresses to amenorrhea with continued use 1. Patients should be counseled about this expected pattern before initiation 1.
Other considerations:
- Weight gain may occur 5
- Return to fertility averages 10 months after last injection but can take up to 22 months 1
- DMPA does not protect against sexually transmitted infections, including HIV 1
Continuation and Follow-Up
No routine follow-up is required 2. Patients should contact their provider to discuss side effects, desire to change methods, or questions about reinjection 2. The continuation rate can be low (18-82.7% at various time points) 4, 6, emphasizing the need for thorough counseling about expected bleeding patterns and BMD concerns.
Drug Interactions
Aminoglutethimide significantly decreases DMPA serum concentrations and may reduce efficacy 1. Certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine) and rifampin/rifabutin may also interact 3.